Key Takeaways

T&L issued an ex-rights disclosure for its bonus issue on August 5. Conventional market wisdom holds that a bonus issue is a positive catalyst — "free shares" tacked onto existing holdings. However, the price adjustment on the ex-rights date is an accounting mechanic, not a change in corporate value — capital surplus is simply reclassified as paid-in capital, and as the share count rises, only the per-share price falls; the total value of a holder's stake theoretically remains unchanged. What actually matters isn't the size of the price adjustment, but whether real buying interest follows after that adjustment.

Disclosure Details

An ex-rights notice is a procedural disclosure announcing the day on which the right to receive new shares from a bonus issue expires. Because buying the stock from the trading day after the new-share allotment record date no longer entitles the buyer to the bonus shares, the exchange opens trading with the reference price lowered to the theoretical ex-rights price. The disclosure itself does not include specific figures such as the issue ratio or the number of new shares, so the actual scale of dilution must be confirmed through a separate filing.

Impact on the Stock

T&L is a KOSDAQ-listed company whose core business is wound dressings, including moist wound dressings. A bonus issue is typically funded from capital surplus rather than retained earnings, so no cash flows out of or into the company. There is no impact on the income statement. That said, as the float expands and the per-share price falls, trading liquidity tends to improve, and the very choice of a bonus issue over a paid-in capital increase can be read as a signal that the company has no urgent need to raise cash. Conversely, fundamentals such as competitive intensity in the wound-care market, cost structure, and export exposure are entirely unchanged by this disclosure — reading the bonus issue as a sign of improving earnings would be an overreach.

Investor Checkpoints

  • Confirm the scheduled date for the new-share listing (change-of-listing) and the actual increase in shares outstanding
  • Watch trading volume and the buyer mix (institutional investors and foreign investors vs. retail investors) in the days following the ex-rights adjustment
  • Check whether wound-dressing revenue growth holds up in the next quarterly earnings release
  • Look for any divergence in share-price performance versus peers in the same industry sector (e.g., Pharmaresearch, Dongkook Pharmaceutical)

Outlook

A bonus issue and its ex-rights adjustment do not, by themselves, change a company's underlying earnings power. If buying momentum continues after the price adjustment, it will be because of genuine growth in the wound-care business, not the bonus issue itself. Conversely, if trading volume balloons and the stock drifts lower without support after the adjustment, the correct reading is that this event amounted to nothing more than a liquidity illusion.

T&L in Real-Time Data

T&L's most recent closing price was 32,200 won (-3.01% versus the previous day), and the signal combining foreign-investor/institutional-investor supply-demand (order flow) with news and momentum reads 🟢 Buy-leaning. Foreign investors and institutional investors are positioned positively, making this a stock worth watching.

  • ▲ Dual buying — foreign investors +1.6 billion won and institutional investors +1.8 billion won, buying in tandem
  • ▼ Trend alignment — short- and medium-term downtrend alignment (-3.0% today · -40.1% over 1 week · -41.8% over 1 month)
  • ▼ 52-week position — in the bottom 3% of the 52-week range

※ Price and foreign/institutional investor supply-demand (order flow) data are provided by Korea Investment & Securities (KIS) and are current as of publication.

📑 This article is an analysis based on T&L's regulatory filing (Ex-Rights (Bonus Issue), 20260805). View original DART filing